Session Chair Profile
M.D., Ph.D., Chief Genomics Officer (CGO), UCSF Health
Biography
Dr. Aleksandar Rajkovic was the Professor and Marcus Allen Hogge Chair in Reproductive Sciences, the Director of the Division of Reproductive Genetics and Medical Director for the Pittsburgh Cytogenetic and Genomic Laboratories in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of Pittsburgh. He recently moved to UCSF to be the Chief Genomics Officer. He serves as the Medical Director and Chief of the Center for Genetic and Genomic Medicine (CGGM) that organizes, coordinates and oversees Clinical Genetics and Genomics Services across the entire UCSF Health System. He is also Stuart Lindsay Distinguished Professor in Experimental Pathology I, member of the American Society of Clinical Investigator and American Association of Physicians. His research interests lie in basic and translational medical sciences in the area of reproductive genetics. Dr. Rajkovic discovered numerous genes that play critical roles in reproductive tract development, male and female infertility, and uterine tumors. He has been at the forefront of applying cutting edge genomic technologies to reproductive diagnostics, including prenatal diagnosis, preimplantation genetic screening, and perinatal genomics. He has made significant contributions to non-invasive diagnosis of submicroscopic deletions, design and utility of dense X chromosome arrays, and utility of genome wide detection of copy number variants in prenatal diagnosis. His current interests lie in whole genome applications towards population based health prediction and prevention, as well as elimination of Mendialian disorders.
Session Abstract – PMWC 2020 Silicon Valley
Session Synopsis: Recently, several unique partnerships for population sequencing studies have been launched. Various medical organizations and pharmaceutical and direct-to-consumer testing companies are included in these partnerships. The designed studies are expected to create new insights, identify new disease targets, and improve individualized patient care. In this session we will hear updates about several of these collaborative population studies to learn about the various opportunities created, the resulting benefits for each of the partners, and the challenges that need to be overcome in relation to data flow and data sharing.
